Research Article

Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Weight in Type 2 Diabetes Mellitus and Therapeutic Regimen Recommendation

Dong-Dong Wang, Yi-Zhen Mao, Yang Yang, Tian-Yun Wang, Ping Zhu, Su-Mei He, and Xiao Chen

1Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy & School of Pharmacy, Xuzhou Medical University, Xuzhou, Jiangsu 221004, China
2School Infirmary, Jiangsu Normal University, Xuzhou, Jiangsu 221132, China
3Department of Pharmacy, The Affiliated Changzhou Children’s Hospital of Nantong University, Changzhou 213003, China
4Department of Pharmacy, Huaian Hospital of Huaian City, Huaian, Jiangsu 223200, China
5Department of Endocrinology, Huaian Hospital of Huaian City, Huaian, Jiangsu 223200, China
6Department of Pharmacy, The Affiliated Suzhou Science & Technology Town Hospital of Nanjing Medical University, Suzhou Jiangsu 215153, China
7Department of Pharmacy, Children’s Hospital of Fudan University, Shanghai 201102, China

Correspondence should be addressed to Dong-Dong Wang; 13852029591@163.com, Ping Zhu; zping1983@163.com, Su-Mei He; hehe8204@163.com, and Xiao Chen; chenxiao112733@163.com

Received 13 October 2021; Revised 17 February 2022; Accepted 1 March 2022; Published 18 March 2022

Aims. The present study is aimed at exploring the effects of sodium-glucose cotransporter-2 (SGLT-2) inhibitors on weight in type 2 diabetes mellitus (T2DM) and therapeutic regimen recommendations. Methods. 20,019 patients with T2DM were enrolled. The maximal effect ($E_{\text{max}}$) models, whose evaluation index was change rate of body weight from baseline value, were used to analyze data using nonlinear mixed effect modeling (NONMEM). Results. For SGLT-2 inhibitors, canagliflozin, empagliflozin, ertugliflozin, ipragliflozin, luseogliflozin, and tofogliflozin, the $E_{\text{max}}$, and treatment duration to reach half of the maximal effects (ET50) were -3.72% and 3.35 weeks, -5.59% and 16.8 weeks, -2.84% and 3.42 weeks, -3.43% and 3.09 weeks, -3.04% and 4.38 weeks, and -2.45% and 3.16 weeks, respectively. In addition, for T2DM patients, 100 mg/day canagliflozin needs to be taken 13.4 weeks for the plateau of effect on weight; 10 mg/day empagliflozin needs to be taken 67.2 weeks for the plateau of effect on weight; 5 mg/day ertugliflozin needs to be taken 13.68 weeks for the plateau of effect on weight; 50 mg/day ipragliflozin needs to be taken 12.36 weeks for the plateau of effect on weight; 2.5 mg/day luseogliflozin needs to be taken 17.52 weeks for the plateau of effect on weight; 20 mg/day tofogliflozin needs to be taken 12.64 weeks for the plateau of effect on weight. Conclusions. This was the first study to explore effects of SGLT-2 inhibitors on weight in T2DM; meanwhile, the optimum dosages and treatment durations on weight from canagliflozin, empagliflozin, ertugliflozin, ipragliflozin, luseogliflozin, and tofogliflozin were recommended, respectively.

1. Introduction

The global epidemic trend of type 2 diabetes mellitus (T2DM) is becoming more and more serious, whose epidemiological data indicating that T2DM approximately impacts 1 in 11 adults [1]. Diabetes and its complications, such as diabetic angiocardiopathy, diabetic nephropathy, diabetic retinopathy, diabetic neuropathy, and diabetic hepatopathy, have serious impact on human health. Additionally, T2DM patients are accompanied by dyslipidemia,
atherosclerotic disease, hypertension, and obesity [2, 3], and what is serious is that more than 50% of T2DM patients have been reported with obesity [3, 4]. All we all know, T2DM patients with overweight or obesity are more likely to increase the risk of cardiovascular disease and lead to further risk increase of death, which are the important determinant of the prognosis of T2DM patients [4, 5]. Thus, it is vital to strengthen management of overweight or obesity in T2DM patients [6].

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors, inhibiting SGLT-2 which is located in the S1 segment of renal proximal tubule and accounts for absorption of nearly 90% of glucose by kidney [7, 8], are a group of antidiabetic drugs. These drugs achieve their potential hypoglycemic activity by virtue of blocking the coupled reuptake of sodium and glucose in proximal tubule and promoting glycosuria [9]. In addition, apart from reducing blood glucose concentration, SGLT-2 inhibitors also have been demonstrated to have nonglycemic pleotropic effects, such as reducing risk of cardiovascular outcomes and mortality [10], attenuating hyperglycemia-induced vascular dysfunction [11], and inducting of weight loss, among which induction of weight loss is one of the important functions, whose mechanisms are due to osmotic diuresis and associated calorie losses [9, 12, 13]. However, the effects of SGLT-2 inhibitors on weight in T2DM are unclear; particularly, the dosages and treatment durations of SGLT-2 inhibitors lack clinical guidance. Therefore, the present study is aimed at exploring the effects of SGLT-2 inhibitors on weight in T2DM and therapeutic regimen recommendations.

2. Methods

2.1. Included Patients. T2DM patients treated with SGLT-2 inhibitors, including canagliflozin, empagliflozin, ertugliflozin, ipragliflozin, luseogliflozin, and tofogliflozin, were enrolled from published literatures, and the researches were approved by the ethics committee of each participating center [12, 14–69]. Search strategy was shown in Supplementary. The inclusion criteria were shown as follows: (a) T2DM patients; (b) with canagliflozin, empagliflozin, ertugliflozin, ipragliflozin, luseogliflozin, and tofogliflozin treatments; (c) randomized controlled trial (RCT); (d) with body weight information; and (e) exact doses and durations of canagliflozin, empagliflozin, ertugliflozin, ipragliflozin, luseogliflozin, and tofogliflozin. Source, grouping, common clinical dosages, duration of treatments, sample size, age, etc. were extracted from the above included studies. Studies identified for analysis were shown in Supplementary Table S1–S6, risk of bias was shown in Supplementary Figure S1–S6, and there was no obvious bias.

The change rates of body weight from baseline values were used as evaluation indices in order to eliminate the potential baseline effect, in which the formula (1) was as follows:

$$\text{EFF}_{\%} = \frac{\text{EFF}_{\text{time}} - \text{EFF}_{\text{base}}}{\text{EFF}_{\text{base}}} \times 100\%.$$  

2.2. Model Establishment. The effects of canagliflozin, empagliflozin, ertugliflozin, ipragliflozin, luseogliflozin, and tofogliflozin on weight loss in T2DM patients were evaluated using the $E_{\text{max}}$ models, respectively. Furthermore, the control effects should be subtracted from the sum effects for acquiring the actual effects on weight loss in T2DM from canagliflozin, empagliflozin, ertugliflozin, ipragliflozin, luseogliflozin, and tofogliflozin. The formulas (2) and (3) were as follows:

$$E_{\text{r,k,i,j}} = E_{\text{a,k,i,j}} - E_{\text{b,k,i,j}}.$$  

$$E_{\text{r,k,i,j}} = \frac{E_{\text{max,k,i,j}} \times \text{Time}}{ET_{50,k,i,j} + \text{Time}} + \frac{E_{\text{b,k,i,j}}}{N_{k,i,j}/100}.$$  

$E_{\text{a,k,i,j}}$ was the sum effects on weight loss in T2DM patients; $E_{\text{b,k,i,j}}$ was the control group effects on weight loss in T2DM patients; $E_{\text{r,k,i,j}}$ was the actual effects on weight loss in T2DM patients; $k$ represented SGLT-2 inhibitors, including canagliflozin, empagliflozin, ertugliflozin, ipragliflozin, luseogliflozin, and tofogliflozin; $i$ was different studies; and $j$ was time point of every study. $E_{\text{max,k}}$ was the maximal effects on weight, $ET_{50,k}$ was the treatment durations to reach half of the maximal effects on weight, $E_{\text{b,k,i,j}}$ was the residual error of study $i$ with time point $j$ under different SGLT-2 inhibitors, and $N_{k,i,j}$ was the sample size in study $i$ with time point $j$ under different SGLT-2 inhibitors, and $E_{\text{r,k,i,j}}$ was weighted by sample size, assumed to be normally distributed, with a mean of 0 and variance of $\sigma^2/(N_{k,i,j}/100)$.

The exponential error or additive error models were used to describe the variabilities of interstudies, in which the formulas (4)-(7) were as follows:

$$E_{\text{max,k,i,j}} = E_{\text{max,k}} \times \exp \left( \eta_{k,1,i,j} \right),$$

$$ET_{50,k,i,j} = ET_{50,k} \times \exp \left( \eta_{k,2,i,j} \right),$$

$$E_{\text{max,k,i,j}} = E_{\text{max,k}} + \eta_{k,1,i,j},$$

$$ET_{50,k,i,j} = ET_{50,k} + \eta_{k,2,i,j}.$$  

$\eta_{k,1,i,j}$ and $\eta_{k,2,i,j}$ were the interstudy variabilities, and when available, they would be added into $E_{\text{max,k}}$ or $ET_{50,k}$, respectively. $k$ represented SGLT-2 inhibitors, including canagliflozin, empagliflozin, ertugliflozin, ipragliflozin, luseogliflozin, and tofogliflozin. $\eta_{k,1,i,j}$ and $\eta_{k,2,i,j}$ were assumed to normally distributed, with a mean of 0 and variance of $\omega_{k,1,i,j}^2$ and $\omega_{k,2,i,j}^2$, respectively.

In addition, continuous covariates and categorical covariates were evaluated by formulas (8)-(10):

$$P_i = P_T + \left( \text{COV} - COV_m \right)\theta_i,$$

$$P_i = P_T \times \left( \text{COV}/COV_m \right)^{\theta_i}.$$
\[ P_i = P_T + \text{COV} \times \theta_c. \quad (10) \]

\( P_i \) was the parameter for a patient with a covariate value of \( \text{COV} \), \( P_T \) was the typical value of the parameter, \( \text{COV} \) was covariate, and \( \text{COV}^m \) was the median value of covariate in the population. \( \theta_c \) was a correction coefficient of the covariate to the model parameter.

The models were established using nonlinear mixed effect modeling (NONMEM, edition 7, ICON Development Solutions, Ellicott City, MD, USA) software. When the basic model was built up, potential covariates were considered for adding into \( E_{\text{max},k} \) or \( ET_{50,k} \). The covariate inclusion criteria were change of objective function value (OFV), where the decrease of OFV was greater than 3.84 (\( \chi^2, \alpha = 0.05, \text{d.f.} = 1 \), it was

**Figure 1:** Visual inspection of routine diagnostic plots: (a) canagliflozin, (b) empagliflozin, (c) ertugliflozin, (d) ipragliflozin, (e) luseogliflozin, and (f) tofogliflozin.
Figure 2: Continued.
considered sufficient for inclusion. When the increase of OFV was greater than 6.63 ($\chi^2$, $\alpha = 0.01$, d.f.: 1), it was considered sufficient for significance in the final model [70].

2.3. Model Validation. The individual predictions vs. observations and individual plots from SGLT-2 inhibitors, including canagliflozin, empagliflozin, ertugliflozin, ipragliflozin, luseogliflozin, and tofogliflozin, were used to estimate the final models, respectively. Prediction-corrected visual predictive check (VPC) plots were used to assess the predictive performance of final models.

2.4. Prediction. The curves of the final models from SGLT-2 inhibitors, including canagliflozin, empagliflozin, ertugliflozin, ipragliflozin, luseogliflozin, and tofogliflozin, were simulated using the Monte Carlo method, in addition, recommending the optimum dosages and treatment durations on weight in T2DM patients from canagliflozin, empagliflozin, ertugliflozin, ipragliflozin, luseogliflozin and tofogliflozin, respectively.

3. Results

3.1. Included Patients. A total of 20,019 patients with T2DM were enrolled in the present study, who were treated with SGLT-2 inhibitors, including canagliflozin, empagliflozin, ertugliflozin, ipragliflozin, luseogliflozin, and tofogliflozin, among which the dosages of canagliflozin, empagliflozin, ertugliflozin, ipragliflozin, luseogliflozin, and tofogliflozin were 100-300 mg/day, 10-25 mg/day, 5-15 mg/day, 50-100 mg/day, 5-15 mg/day, 50-100 mg/day, 2.5-5 mg/day, and 20-40 mg/day, respectively [12, 14–69].

3.2. Modeling. For canagliflozin, empagliflozin, ertugliflozin, ipragliflozin, luseogliflozin, and tofogliflozin, the $E_{max}$ and ET$_{50}$ were -3.72% and 3.35 weeks, -5.59% and 16.8 weeks, -2.84% and 3.42 weeks, -3.43% and 3.09 weeks, -3.04% and 4.38 weeks, and -2.45% and 3.16 weeks, respectively. The bootstrap method results were shown in Supplementary Table S7, and estimate values were within the limits of 95% bootstrap confidence interval. In these T2DM patients, no covariate (in particular dosage) was incorporated into models, showing no significant dosage response.

Figure 2: Individual plots: (a) canagliflozin, (b) empagliflozin, (c) ertugliflozin, (d) ipragliflozin, (e) luseogliflozin, and (f) tofogliflozin. Different IDs come from different groups of RCTs [12, 14–69].
Figure 3: Continued.
relationship within the current dose ranges. In other words, it was eligible to choose the lower dose of the dosage ranges, and for canagliozin, empagliozin, ertugliozin, ipragliozin, luseogliozin, and tofogliozin, the recommended dosages were 100 mg/day, 10 mg/day, 5 mg/day, 50 mg/day, 2.5 mg/day, and 20 mg/day, respectively.

In addition, the relationships between SGLT-2 inhibitors, including canagliozin, empagliozin, ertugliozin, ipragliozin, luseogliozin, and tofogliozin, and loss of weight in T2DM patients, were shown in formulas (11)–(16), respectively:

\[
\text{EFF} = \frac{-3.72\% \times \text{Time}}{3.35 + \text{Time}},
\]

\[
\text{EFF} = \frac{-5.59\% \times \text{Time}}{16.8 + \text{Time}},
\]

\[
\text{EFF} = \frac{-2.84\% \times \text{Time}}{3.42 + \text{Time}},
\]

\[
\text{EFF} = \frac{-3.43\% \times \text{Time}}{3.09 + \text{Time}},
\]

\[
\text{EFF} = \frac{-3.04\% \times \text{Time}}{4.38 + \text{Time}},
\]

\[
\text{EFF} = \frac{-2.45\% \times \text{Time}}{3.16 + \text{Time}}.
\]

EFF was canagliozin, empagliozin, ertugliozin, ipragliozin, luseogliozin, and tofogliozin on the effects of weight loss in T2DM patients.

3.3. Evaluation. The individual predictions vs. observations from canagliozin, empagliozin, ertugliozin, ipragliozin, luseogliozin, and tofogliozin models were shown in Figure 1, and Figures 1(a)–1(f) were from canagliozin, empagliozin, ertugliozin, ipragliozin, luseogliozin, and tofogliozin, respectively, showing good linear relationships between individual predictions and observations and indicating the better fitting of the final models. Individual plots were shown in Figure 2, and Figures 2(a)–2(f) were from canagliozin, empagliozin, ertugliozin, ipragliozin, luseogliozin, and tofogliozin, respectively, demonstrating acceptable predictability from the perspective of clinical sparse data. The prediction-corrected VPC plots were shown in Figure 3, and Figures 3(a)–3(f) were from canagliozin, empagliozin, ertugliozin, ipragliozin, luseogliozin, and tofogliozin, respectively, indicating that most observed data were included in the 95% prediction intervals produced with simulation data and meaning the predictive power of the final models.

3.4. Prediction. The trends of efficacy of canagliozin, empagliozin, ertugliozin, ipragliozin, luseogliozin, and tofogliozin on the effects of weight loss in T2DM patients were shown in Figure 4. For canagliozin, as shown in Figure 4(a), the duration to achieve 25%, 50%, 75%, and 80% of \(E_{\text{max}}\) was 1.12, 3.35, 10.05, and 13.4 weeks. For empagliozin, as shown in Figure 4(b), the duration to achieve 25%, 50%, 75%, and 80% of \(E_{\text{max}}\) was 5.6, 16.8, 50.4, and 67.2 weeks. For ertugliozin, as shown in Figure 4(c), the duration to achieve 25%, 50%, 75%, and 80% of \(E_{\text{max}}\) was 1.14, 3.42, 10.26, and 13.68 weeks. For ipragliozin, as shown in Figure 4(d), the duration to achieve 25%, 50%, 75%, and 80% of \(E_{\text{max}}\) was 1.03, 3.09, 9.27, and 12.36 weeks. For luseogliozin, as shown in Figure 4(e), the duration to
achieve 25%, 50%, 75%, and 80% of $E_{\text{max}}$ was 1.46, 4.38, 13.14, and 17.52 weeks. For tofogliflazin, as shown in Figure 4(f), the duration to achieve 25%, 50%, 75%, and 80% of $E_{\text{max}}$ was 1.05, 3.16, 9.48, and 12.64 weeks.

In addition, as the study had found in the front section that the recommended dosages of canagliflazin, empagliflazin, ertugliflazin, ipragliflazin, luseogliflazin, and tofogliflazin were 100 mg/day, 10 mg/day, 5 mg/day, 50 mg/day,
2.5 mg/day, and 20 mg/day, respectively. Therefore, to achieve the plateau period (80% of $E_{\text{max}}$) in loss of weight in T2DM patients, 100 mg/day canagliflozin needs to be taken 13.4 weeks for the plateau of effect on weight; 10 mg/day empagliflozin needs to be taken 67.2 weeks for the plateau of effect on weight; 5 mg/day ertugliflozin needs to be taken 12.36 weeks for the plateau of effect on weight; 2.5 mg/day luseogliflozin needs to be taken 17.52 weeks for the plateau of effect on weight; 20 mg/day tofogliflozin needs to be taken 12.64 weeks for the plateau of effect on weight.

4. Discussion

At present, many studies have found that SGLT-2 inhibitors, including canagliflozin, empagliflozin, ertugliflozin, ipragliflozin, luseogliflozin, and tofogliflozin, can reduce weight in T2DM patients, playing an important role in the treatment of T2DM [12, 14–69]. However, the effects of dosages and treatment durations of SGLT-2 inhibitors on weight in T2DM lack clinical guidance. Therefore, the present study is aimed at exploring the effects of SGLT-2 inhibitors on weight in T2DM and therapeutic regimen recommendations.

The present study adopts $E_{\text{max}}$ models, the practical quantitative pharmacology tool, which can be used to explore the recommendation of drug dose and course of treatment in the course of disease treatment, and lay the foundation for the formulation of drug treatment plan. So far, many related studies have been reported. For example, Farhan et al. reported development and verification of a body weight-directed disease trial model for glucose homeostasis [71]. Chen et al. reported time course and dose effect of metformin on weight in patients with different disease states [72]. Li et al. reported comparative efficacy of nonhormonal drugs on menopausal hot flashes [73]. Wang et al. reported quantitative efficacy of L-carnitine supplementation on glycemic control in type 2 diabetes mellitus patients [74]. Chen et al. reported analysis of time course and dose effect of tacrolimus on proteinuria in lupus nephritis patients [75]. Li et al. reported quantitative efficacy of soy isoflavones on menopausal hot flashes [76]. Thus, we used this utility tool to explore the optimum dosages and treatment durations on weight from canagliflozin, empagliflozin, ertugliflozin, ipragliflozin, luseogliflozin, and tofogliflozin, respectively.

The nonlinear mixed effect modeling (NONMEM) was used to analyze. In the process of our research, the evaluation index was change rate of body weight from baseline value in order to eliminate the potential baseline effect. In addition, the control effects were subtracted from the sum effects for obtaining the actual effects on weight loss in T2DM from canagliflozin, empagliflozin, ertugliflozin, ipragliflozin, luseogliflozin, and tofogliflozin. Finally, for canagliflozin, empagliflozin, ertugliflozin, ipragliflozin, luseogliflozin, and tofogliflozin, the $E_{\text{max}}$ and $ET_{50}$ were -3.72% and 3.35 weeks, -5.59% and 16.8 weeks, -2.84% and 3.42 weeks, -3.43% and 3.09 weeks, -3.04% and 4.38 weeks, and -2.45% and 3.16 weeks, respectively. The order of efficacy of canagliflozin, empagliflozin, ertugliflozin, ipragliflozin, luseogliflozin, and tofogliflozin on the effects of weight loss in T2DM patients from large to small was 10 mg/day empagliflozin, 100 mg/day canagliflozin, 50 mg/day ipragliflozin, 2.5 mg/day luseogliflozin, 5 mg/day ertugliflozin, and 20 mg/day tofogliflozin. The onset time of weight loss from fast to slow was 50 mg/day ipragliflozin, 20 mg/day tofogliflozin, 100 mg/day canagliflozin, 5 mg/day ertugliflozin, 2.5 mg/day luseogliflozin, and 10 mg/day empagliflozin.

Besides, the optimum dosages and treatment durations on weight from canagliflozin, empagliflozin, ertugliflozin, ipragliflozin, luseogliflozin, and tofogliflozin were recommended in T2DM patients, respectively. 100 mg/day canagliflozin needs to be taken 13.4 weeks for the plateau of effect on weight; 10 mg/day empagliflozin needs to be taken 67.2 weeks for the plateau of effect on weight; 5 mg/day ertugliflozin needs to be taken 13.68 weeks for the plateau of effect on weight; 50 mg/day ipragliflozin needs to be taken 12.36 weeks for the plateau of effect on weight; 2.5 mg/day luseogliflozin needs to be taken 17.52 weeks for the plateau of effect on weight; 20 mg/day tofogliflozin needs to be taken 12.64 weeks for the plateau of effect on weight.

The present study firstly explored the effects of canagliflozin, empagliflozin, ertugliflozin, ipragliflozin, luseogliflozin, and tofogliflozin on weight in T2DM and recommended therapeutic regimen. However, this study also had some limitations. For example, the studies of luseogliflozin and tofogliflozin were all from Japan and lack of data on other countries’ populations. This required further population expansion and inclusion of populations from more countries in future studies.

5. Conclusion

This was the first comprehensive study to explore effects of SGLT-2 inhibitors on weight in T2DM; meanwhile, the optimum dosages and treatment durations on weight from canagliflozin, empagliflozin, ertugliflozin, ipragliflozin, luseogliflozin, and tofogliflozin were recommended, respectively.

Data Availability

The data related to this article can be publicly available after the article accepted.

Conflicts of Interest

The authors have no conflicts of interest to declare.

Authors’ Contributions

Conception and design were contributed by D Wang, P Zhu, S He, and X Chen. Collection and assembly of data were contributed by D Wang, Y Mao, Y Yang, T Wang, P Zhu, S He, and X Chen. Data analysis and interpretation were contributed by D Wang. Manuscript writing was contributed by D Wang. Final approval of the manuscript was...
approved by all authors. Dong-Dong Wang, Yi-Zhen Mao, Yang Yang, and Tian-Yun Wang contributed equally to this work and are co-first authors.

Acknowledgments

This work was supported by the Initializing Fund of Xuzhou Medical University (No. RC20552111), the Fusion Innovation Project of Xuzhou Medical University (No. XYRHCX2021011), the Xuzhou Special Fund for Promoting Scientific and Technological Innovation (No. KC21257), the Suzhou Science & Technology Town Hospital Pre-Research Fund Project (No. 2019Y01), the Suzhou Science and Technology Development Plan Project (No. SYSD2019076), and the Jiangsu Pharmaceutical Society-Tianqing Hospital Pharmaceutical Fund Project (No. Q202024).

Supplementary Materials

The Supplementary Materials have been submitted along with the primary manuscript, including search strategy, studies identified for analysis, risk of bias, and parameter estimates of final models and bootstrap. (Supplementary Materials)

References

[1] P. Saeedi, I. Petersohn, P. Salpea et al., “Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition,” Diabetes Research and Clinical Practice, vol. 157, article 107843, 2019.

[2] P. González-Muniesa, M.-A. Martínez-González, F. B. Hu et al., "Obesity," Nature Reviews. Disease Primers, vol. 3, no. 1, p. 17034, 2017.

[3] K. Iglay, H. Hannachi, P. Joseph Howie et al., "Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus," Current Medical Research and Opinion, vol. 32, no. 7, pp. 1243–1252, 2016.

[4] T. R. Einarson, A. Acs, C. Ludwig, and U. H. Panton, “Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017,” Cardiovascular Diabetology, vol. 17, no. 1, p. 83, 2018.

[5] American Diabetes A, "8. Obesity management for the treatment of type 2 diabetes:standards of medical care in diabetes-2020," Diabetes Care, vol. 43, Supplement_1, pp. S89–S97, 2020.

[6] K. Ueda, Y. Kawai, T. Yamada et al., "Systematic review and meta-analysis for prevention of cardiovascular complications using GLP-1 receptor agonists and SGLT-2 inhibitors in obese diabetic patients," Scientific Reports, vol. 11, no. 1, article 10166, 2021.

[7] R. J. Turner and A. Moran, "Heterogeneity of sodium-dependent D-glucose transport sites along the proximal tubule: evidence from vesicle studies," The American Journal of Physiology, vol. 242, no. 4, pp. F406–F414, 1982.

[8] A. Kashiwagi and H. Maegawa, "Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitus," Journal of Diabetes Investigation, vol. 8, no. 4, pp. 416–427, 2017.

[9] N. Mittal, V. Sehrajt, R. Mittal, and S. Singh, “Reno-protective potential of sodium glucose cotransporter-2 (SGLT2) inhibitors: summary evidence from clinical and real-world data,” European Journal of Pharmacology, vol. 907, article 174320, 2021.

[10] A. Mascolo, C. Scavone, L. Scisciola, P. Chiodini, A. Capuano, and G. Paolasso, “SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: a systematic review and meta-analysis of retrospective cohort studies,” Pharmacological Research, vol. 172, article 105836, 2021.

[11] N. D’Onofrio, C. Sardu, M. C. Trotta et al., “Sodium-glucose co-transporter2 expression and inflammatory activity in diabetic atherosclerotic plaques: effects of sodium-glucose co-transporter2 inhibitor treatment,” Molecular Metabolism, vol. 54, article 101337, 2021.

[12] S. Sha, D. Polidori, T. Heise et al., “Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus,” Diabetes, Obesity & Metabolism, vol. 16, no. 11, pp. 1087–1095, 2014.

[13] H. J. Heerspink, B. A. Perkins, D. H. Fitchett, M. Husain, and D. Z. I. Cherney, “Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes Mellitus,” Circulation, vol. 134, no. 10, pp. 752–772, 2016.

[14] J. F. Yale, J. Xie, S. E. Sherman, and C. Garceau, “Canagliflozin in conjunction with sulfonylurea maintains glycemic control and weight loss over 52 weeks: a randomized, controlled trial in patients with type 2 diabetes mellitus,” Clinical Therapeutics, vol. 39, no. 11, pp. 2230–2242.e2, 2017.

[15] T. Kadowaki, N. Inagaki, K. Kondo et al., “Efficacy and safety of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: results of a 24-week, randomized, double-blind, placebo-controlled trial,” Diabetes, Obesity & Metabolism, vol. 19, no. 6, pp. 874–882, 2017.

[16] N. Inagaki, S. Harashima, N. Maruyama, Y. Kawaguchi, M. Goda, and H. Iijima, “Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus,” Cardiovascular Diabetology, vol. 15, no. 1, p. 89, 2016.

[17] H. W. Rodbard, J. Seufert, N. Aggarwal et al., “Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin,” Diabetes, Obesity & Metabolism, vol. 18, no. 8, pp. 812–819, 2016.

[18] J. Rosenstock, L. Chuck, M. González-Ortiz et al., “Initial combination therapy with canagliflozin plus metformin versus each component as monotherapy for drug-naïve type 2 diabetes,” Diabetes Care, vol. 39, no. 3, pp. 353–362, 2016.

[19] G. Fulcher, D. R. Matthews, V. Perkovic et al., “Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes,” Diabetes, Obesity & Metabolism, vol. 18, no. 1, pp. 82–91, 2016.

[20] B. Bode, K. Stenlöf, S. Harris et al., “Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55–80 years with type 2 diabetes,” Diabetes, Obesity & Metabolism, vol. 17, no. 3, pp. 294–303, 2015.

[21] B. Neal, V. Perkovic, D. de Zeeuw et al., “Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with...
type 2 diabetes,” *Diabetes Care*, vol. 38, no. 3, pp. 403–411, 2015.

[22] L. Ji, P. Han, Y. Liu et al., "Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea," *Diabetes, Obesity & Metabolism*, vol. 17, no. 1, pp. 23–31, 2015.

[23] N. Inagaki, K. Kondo, T. Yoshinari, N. Takahashi, Y. Susuta, and H. Kuki, "Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, Phase III study," *Expert Opinion on Pharmacotherapy*, vol. 15, no. 11, pp. 1501–1515, 2014.

[24] J. F. Yale, G. Bakris, B. Cariou et al., "Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease," *Diabetes, Obesity & Metabolism*, vol. 16, no. 10, pp. 1016–1027, 2014.

[25] T. Forst, R. Guthrie, R. Goldenberg et al., "Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone," *Diabetes, Obesity & Metabolism*, vol. 16, no. 5, pp. 467–477, 2014.

[26] J. P. Wilding, G. Charpentier, P. Hollander et al., "Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial," *International Journal of Clinical Practice*, vol. 67, no. 12, pp. 1267–1282, 2013.

[27] N. Inagaki, K. Kondo, T. Yoshinari, N. Maruyama, Y. Susuta, and H. Kuki, "Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study," *Diabetes, Obesity & Metabolism*, vol. 15, no. 12, pp. 1136–1145, 2013.

[28] K. Stenlöf, W. T. Cefalu, K. A. Kim et al., "Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise," *Diabetes, Obesity & Metabolism*, vol. 15, no. 4, pp. 372–382, 2013.

[29] J. Rosenstock, N. Aggarwal, D. Polidori et al., "Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes," *Diabetes Care*, vol. 35, no. 6, pp. 1232–1238, 2012.

[30] D. Devineni, L. Morrow, M. Hompesch et al., "Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin," *Diabetes, Obesity & Metabolism*, vol. 14, no. 6, pp. 539–545, 2012.

[31] S. Kahl, S. Gancheva, K. Straßburger et al., "Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4, placebo-controlled trial," *Diabetes Care*, vol. 43, no. 2, pp. 298–305, 2020.

[32] S. Hattori, "Empagliflozin decreases remnant-like particle cholesterol in type 2 diabetes patients with insulin resistance," *Journal of Diabetes Investigation*, vol. 9, no. 4, pp. 870–874, 2018.

[33] E. Søfteland, J. J. Meier, B. Vangen, R. Toorawa, M. Maldonado-Lutomirsky, and U. C. Broedel, "Empagliflozin as add-on therapy in patients with type 2 diabetes inadequately controlled with linagliptin and metformin: a 24-week randomized, double-blind, parallel-group trial," *Diabetes Care*, vol. 40, no. 2, pp. 201–209, 2017.

[34] S. Hadjadi, J. Rosenstock, T. Meinicke, H. J. Woerle, and U. C. Broedel, "Initial combination of empagliflozin and metformin in patients with type 2 diabetes," *Diabetes Care*, vol. 39, no. 10, pp. 1718–1728, 2016.

[35] M. Roden, L. Merker, A. V. Christiansen et al., "Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a phase III randomized controlled trial," *Cardiovascular Diabetology*, vol. 14, no. 1, p. 154, 2015.

[36] J. Rosenstock, A. Jelaska, C. Zeller et al., "Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial," *Diabetes, Obesity & Metabolism*, vol. 17, no. 10, pp. 936–948, 2015.

[37] L. Merker, H. U. Häring, A. V. Christiansen et al., "Empagliflozin as add-on to metformin in people with type 2 diabetes," *Diabetic Medicine*, vol. 32, no. 12, pp. 1555–1567, 2015.

[38] R. A. DeFronzo, A. Lewin, S. Patel et al., "Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin," *Diabetes Care*, vol. 38, no. 3, pp. 384–393, 2015.

[39] T. Kadowaki, M. Haneda, N. Inagaki et al., "Empagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, 12-week, double-blind, placebo-controlled, phase II trial," *Advances in Therapy*, vol. 31, no. 6, pp. 621–638, 2014.

[40] H. U. Häring, L. Merker, E. Seewaldt-Becker et al., "Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial," *Diabetes Care*, vol. 37, no. 6, pp. 1650–1659, 2014.

[41] E. Ferrannini, A. Berk, S. Hantel et al., "Long-term safety and efficacy of empagliflozin, sitagliptin, and Metformin," *Diabetes Care*, vol. 36, no. 12, pp. 4015–4021, 2013.

[42] C. S. Kovacs, V. Seshiah, R. Swallow et al., "Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial," *Diabetes, Obesity & Metabolism*, vol. 16, no. 2, pp. 147–158, 2014.

[43] J. Rosenstock, L. J. Seman, A. Jelaska et al., "Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia," *Diabetes, Obesity & Metabolism*, vol. 15, no. 12, pp. 1154–1160, 2013.

[44] H. U. Häring, L. Merker, E. Seewaldt-Becker et al., "Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial," *Diabetes Care*, vol. 36, no. 11, pp. 3396–3404, 2013.

[45] E. Ferrannini, L. Seman, E. Seewaldt-Becker, S. Hantel, S. Pinnetti, and H. J. Woerle, "A phase Ib, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes," *Diabetes, Obesity & Metabolism*, vol. 15, no. 8, pp. 721–728, 2013.

[46] L. Ji, Y. Liu, H. Miao et al., "Safety and efficacy of etrugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia," *Diabetes, Obesity & Metabolism*, vol. 21, no. 6, pp. 1474–1482, 2019.

[47] S. Gallo, B. Charbonnel, A. Goldman et al., "Long-term efficacy and safety of etrugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial," *Diabetes, Obesity & Metabolism*, vol. 21, no. 4, pp. 1027–1036, 2019.

[48] R. Aronson, J. Frias, A. Goldman, A. Darekar, B. Lauring, and S. G. Terra, "Long-term efficacy and safety of etrugliflozin
monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study,” *Diabetes, Obesity & Metabolism*, vol. 20, no. 6, pp. 1453–1460, 2018.

[49] R. E. Pratley, R. Eldor, A. Raji et al., “Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: the VERTIS FACTORIAL randomized trial,” *Diabetes, Obesity & Metabolism*, vol. 20, no. 5, pp. 1111–1120, 2018.

[50] S. Dagogo-Jack, J. Liu, R. Eldor et al., “Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: the VERTIS SITA2 placebo-controlled randomized study,” *Diabetes, Obesity & Metabolism*, vol. 20, no. 3, pp. 530–540, 2018.

[51] N. B. Amin, X. Wang, S. M. Jain, D. S. Lee, G. Nucci, and J. M. Rusnak, "Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin," *Diabetes, Obesity & Metabolism*, vol. 17, no. 6, pp. 591–598, 2015.

[52] G. Grunberger, S. Camp, J. Johnson et al., "Ertugliflozin in patients with stage 3 chronic kidney disease and type 2 diabetes mellitus: the VERTIS RENAL randomized study," *Diabetes Therapy*, vol. 9, no. 1, pp. 49–66, 2018.

[53] H. Inoue, K. Morino, S. Ugi et al., "Ipragliflozin, a sodium–glucose co-transporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: a randomized clinical trial," *Journal of Diabetes Investigation*, vol. 10, no. 4, pp. 1012–1021, 2019.

[54] M. V. Shestakova, J. P. H. Wilding, W. Wilpshaar, R. Tretter, V. L. Orlova, and A. F. Verbovoy, "A phase 3 randomized placebo-controlled trial to assess the efficacy and safety of irtugliflozin as an add-on therapy to metformin in Russian patients with inadequately controlled type 2 diabetes mellitus," *Diabetes Research and Clinical Practice*, vol. 146, pp. 240–250, 2018.

[55] K. A. Han, S. Chon, C. H. Chung et al., "Efficacy and safety of ipragliflozin as an add-on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: a randomized controlled trial," *Diabetes, Obesity & Metabolism*, vol. 20, no. 10, pp. 2408–2415, 2018.

[56] H. Ishihara, S. Yamaguchi, I. Nakao, A. Oikitsu, and S. Asahina, "Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a multi-centre, randomized, placebo-controlled, double-blind study," *Diabetes, Obesity & Metabolism*, vol. 18, no. 12, pp. 1207–1216, 2016.

[57] A. Kashiwagi, H. Takahashi, H. Ishikawa et al., "A randomized, double-blind, placebo-controlled study on long-term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the long-term ASP1941 safety evaluation in patients with type 2 diabetes with renal impairment (LANTERN) study," *Diabetes, Obesity & Metabolism*, vol. 17, no. 2, pp. 152–160, 2015.

[58] A. Kashiwagi, K. Kazuta, K. Goto, S. Yoshida, E. Ueyama, and A. Utsuno, "Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double-blind, placebo-controlled study," *Diabetes, Obesity & Metabolism*, vol. 17, no. 3, pp. 304–308, 2015.

[59] T. Kodokura, N. Akiyama, A. Kashiwagi et al., "Pharmacokinetic and pharmacodynamic study of ipragliflozin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study," *Diabetes Research and Clinical Practice*, vol. 106, no. 1, pp. 50–56, 2014.

[60] V. A. Fonseca, E. Ferrannini, J. P. Wilding et al., "Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus," *Journal of Diabetes and Its Complications*, vol. 27, no. 3, pp. 268–273, 2013.

[61] J. P. Wilding, E. Ferrannini, V. A. Fonseca, W. Wilpshaar, P. Dhanjal, and A. Houzer, "Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study," *Diabetes, Obesity & Metabolism*, vol. 15, no. 5, pp. 403–409, 2013.

[62] S. L. Schwartz, B. Akinlade, S. Klasen, D. Kowalski, W. Zhang, and W. Wilpshaar, "Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus," *Diabetes Technology & Therapeutics*, vol. 13, no. 12, pp. 1219–1227, 2011.

[63] Y. Seino, T. Sasaki, A. Fukatsu, H. Imazeki, H. Ochiai, and S. Sakai, "Efficacy and safety of luseogliflozin added to insulin therapy in Japanese patients with type 2 diabetes: a multicenter, 52-week, clinical study with a 16-week, double-blind period and a 36-week, open-label period," *Current Medical Research and Opinion*, vol. 34, no. 6, pp. 981–994, 2018.

[64] Y. Seino, T. Sasaki, A. Fukatsu, M. Uebukata, S. Sakai, and Y. Samukawa, "Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study," *Current Medical Research and Opinion*, vol. 30, no. 7, pp. 1245–1255, 2014.

[65] Y. Seino, T. Sasaki, A. Fukatsu, M. Uebukata, S. Sakai, and Y. Samukawa, "Dose-finding study of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, double-blind, placebo-controlled, phase II study," *Current Medical Research and Opinion*, vol. 30, no. 7, pp. 1231–1244, 2014.

[66] Y. Seino, T. Sasaki, A. Fukatsu, S. Sakai, and Y. Samukawa, "Efficacy and safety of luseogliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, placebo-controlled, phase II study," *Current Medical Research and Opinion*, vol. 30, no. 7, pp. 1219–1230, 2014.

[67] Y. Terauchi, M. Tamura, M. Senda, R. Gunji, and K. Kaku, "Long-term safety and efficacy of tofogliflozin as add-on to insulin in patients with type 2 diabetes: results from a 52-week, multicentre, randomized, double-blind, open-label extension, phase 4 study in Japan (J-STEP/INS)," *Diabetes, Obesity & Metabolism*, vol. 20, no. 5, pp. 1176–1185, 2018.

[68] S. Ikeda, Y. Takano, O. Cynshi et al., "A novel and selective sodium-glucose co-transporter-2 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus," *Diabetes, Obesity & Metabolism*, vol. 17, no. 10, pp. 984–993, 2015.

[69] K. Kaku, H. Watada, Y. Iwamoto et al., "Efficacy and safety of monotherapy with the novel sodium/glucose co-transporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study," *Cardiovascular Diabetology*, vol. 13, no. 1, p. 65, 2014.

[70] D. D. Wang, Y. Z. Mao, S. M. He, and X. Chen, "Analysis of time course and dose effect from metformin on body mass
index in children and adolescents,” *Frontiers in Pharmacology*, vol. 12, article 611480, 2021.

[71] N. Farhan, I. Gebert, Y. Xing et al., “Development and verification of a body weight–directed disease trial model for glucose homeostasis,” *Journal of Clinical Pharmacology*, vol. 61, no. 2, pp. 234–243, 2021.

[72] X. Chen, D. D. Wang, and Z. P. Li, “Time course and dose effect of metformin on weight in patients with different disease states,” *Expert Review of Clinical Pharmacology*, vol. 13, no. 10, pp. 1169–1177, 2020.

[73] L. Li, L. Xu, J. Wu, L. Dong, S. Zhao, and Q. Zheng, “Comparative efficacy of nonhormonal drugs on menopausal hot flashes,” *European Journal of Clinical Pharmacology*, vol. 72, no. 9, pp. 1051–1058, 2016.

[74] D. D. Wang, Y. Z. Mao, S. M. He, Y. Yang, and X. Chen, “Quantitative efficacy of L-carnitine supplementation on glycemic control in type 2 diabetes mellitus patients,” *Expert Review of Clinical Pharmacology*, vol. 14, no. 7, pp. 919–926, 2021.

[75] X. Chen, D. D. Wang, and Z. P. Li, “Analysis of time course and dose effect of tacrolimus on proteinuria in lupus nephritis patients,” *Journal of Clinical Pharmacy and Therapeutics*, vol. 46, no. 1, pp. 106–113, 2021.

[76] L. Li, Y. Lv, L. Xu, and Q. Zheng, “Quantitative efficacy of soy isoflavones on menopausal hot flashes,” *British Journal of Clinical Pharmacology*, vol. 79, no. 4, pp. 593–604, 2015.